
ODAC Votes STARGLO Trial Not Applicable to US Patients With DLBCL
The FDA’s Oncologic Drug Advisory Committee (ODAC) has voted 8 to 1 that findings from the phase 3, confirmatory STARGLO trial (NCT04408638) evaluating glofitamab-gxbm (Columvi) in addition to gemcitabine and oxaliplatin (GemOx) for the treatment of …